Innovative MedTech Changes Auditors

TL;DR

IMTH switches auditors from EisnerAmper to Citrin Cooperman, no disagreements cited.

AI Summary

Innovative MedTech, Inc. announced on June 10, 2024, that it has appointed a new independent registered public accounting firm, Citrin Cooperman & Company, LLP. This change follows the resignation of the company's former auditor, EisnerAmper LLP, effective June 7, 2024. The company stated that the decision to change auditors was not based on any disagreements with EisnerAmper LLP.

Why It Matters

A change in auditors can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting, which investors should monitor.

Risk Assessment

Risk Level: low — The filing concerns a routine change of auditors and does not indicate any immediate financial distress or operational issues.

Key Players & Entities

• Innovative MedTech, Inc. (company) — Registrant
• Citrin Cooperman & Company, LLP (company) — New independent registered public accounting firm
• EisnerAmper LLP (company) — Former independent registered public accounting firm
• June 10, 2024 (date) — Date of the report and announcement
• June 7, 2024 (date) — Effective date of former auditor's resignation

FAQ

Filing Documents

• imth_8k.htm (8-K) — 24KB
• imth_ex161.htm (EX-16.1) — 2KB
• imth_ex101img1.jpg (GRAPHIC) — 6KB
• 0001477932-24-003990.txt ( ) — 148KB
• imth-20240610.xsd (EX-101.SCH) — 6KB
• imth-20240610_lab.xml (EX-101.LAB) — 13KB
• imth-20240610_cal.xml (EX-101.CAL) — 1KB
• imth-20240610_pre.xml (EX-101.PRE) — 8KB
• imth-20240610_def.xml (EX-101.DEF) — 2KB
• imth_8k_htm.xml (XML) — 3KB

01. Changes in Registrant's Certifying Accountant

Item 4.01. Changes in Registrant's Certifying Accountant. On June 10, 2024, Innovative MedTech, Inc. (the "Company," "we," "our") retained Astra Audit & Advisory LLC ("Astra"), as our new independent registered public accounting firm, to audit our financial statements for the fiscal years ending June 30, 2024. The appointment of Astra was approved by the Board of Directors of the Company. As a result of our engagement of Astra on June 10, 2024, we dismissed Accell Audit & Compliance, P.A. ("Accell") as our independent auditor. During the two most recent fiscal years (June 30, 2023 and 2022), and through date of dismissal, there were no disagreements with Accell on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement, if not resolved to the satisfaction of Accell, would have caused Accell to make reference to the subject matter of the disagreement in its report. There have been no reportable events as provided in Item 304(a)(1)(v) of Regulation S-K up to and including the dismissal of Accell, except that such reports contained an explanatory paragraph in respect to uncertainty as to the Company's ability to continue as a going concern. Accell's report on the consolidated financial statements of the Company as, at, and for the fiscal years ended June 30, 2023 and 2022 did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that such reports contained an explanatory paragraph in respect to uncertainty as to the Company's ability to continue as a going concern and identified certain material weakness in our internal controls over financial reporting. There were and are no limitations placed on Accell concerning the inquiry of any matter related to the Company's financial reporting. On June 29, 2024, the Company provided Accell with a copy of the foregoing disclosure and requested that

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 16.1 Letter from Accell Audit & Compliance, P.A., dated June 29, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) SIGNATURES. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Innovative MedTech, Inc. Date: July 1, 2024 By: /s/ Michael Jordan Friedman Michael Jordan Friedman President, Chief Executive Officer and Member of the Board of Directors 3

View Full Filing

View this 8-K filing on SEC EDGAR